Advanced Enzyme Technologies has unveiled a ₹697 million share repurchase plan alongside quarterly results, a step that underscores its strategic focus on capital return and acquiring full control of JC Biotech as it reports sustained financial performance.
Advanced Enzyme Technologies on Saturday unveiled a share buyback of up to ₹697 million, adding a capital return plan to a day that also brought quarterly results and fresh moves on two subsidiaries. The board, meeting in Thane, authorised the repurchase of as many as 1,394,000 equity shares at up to ₹500 apiece through stock exchanges, a programme equal to 1.24% of the company’s paid-up equity capital. Promoters and the promoter group will stay out of the offer, and the company said a buyback committee will handle execution after a public announcement sets the timetable.
The enzyme maker also moved to tighten its grip on JC Biotech Private Limited by agreeing to buy the remaining 4.28% from existing shareholders for ₹79.79 million, or ₹90 a share. JC Biotech, which makes biopharmaceuticals through aerobic fermentation, reported turnover of ₹728 million in FY2026. Advanced Enzymes already owns 95.72% and expects the subsidiary to become wholly owned by September 30, 2026.
In a separate decision, the company approved an infusion of up to ₹20 million into Advanced Nutrazyme Private Limited, its wholly owned nutrition and wellness arm, through equity or an inter-corporate deposit in one or more tranches by December 31, 2027. On the operating side, Advanced Enzyme reported consolidated revenue from operations of ₹1,897.88 million for the quarter ended June 30, 2026, up from ₹1,859.14 million a year earlier, while consolidated net profit eased to ₹385.89 million from ₹404.40 million. Standalone revenue came in at ₹1,158.57 million and standalone profit at ₹223.46 million.
The latest figures add to a broader run of solid performance. Mint reported that quarterly consolidated revenue rose 16.4% from the previous quarter in Q1 FY2025-26, with net profit up 38.6% quarter on quarter. Business Standard said the company had already posted a 62.24% rise in consolidated net profit in the March 2026 quarter, alongside sales growth of 21.65%, while market data suggest the group remains profitable and that its next earnings date is due on August 14, 2026.
Disclaimer: This article is intended to inform and educate, not to recommend or endorse any financial product, investment or strategy. Please consider your own financial circumstances and seek professional advice where appropriate before making financial decisions.
